Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma
Study Status
Open to Enrollment
Study Description
This clinical trial is for women with platinum sensitive recurrent ovarian cancer. “Platinum sensitive” means those with relapsed disease who had an initial complete remission, and then relapsed more than 6 months after completing initial platinum-based chemotherapy treatment for ovarian, primary peritoneal or fallopian tube cancer.
The purpose of the study is to determine if adding the drug Pemetrexed to Carboplatin helps improve response to therapy in the treatment of recurrent ovarian cancer.
Currently, Carboplatin alone is one of the standard treatments for recurrent ovarian, primary peritoneal or fallopian tube cancer. Pemetrexed is a promising therapy for ovarian cancer treatment. The combination of Pemetrexed with Carboplatin has been used to treat other types of cancer, and adding Pemetrexed to Carboplatin may improve response better than Carboplatin alone for recurrent ovarian cancer.
Study participants will receive a dose of Pemetrexed via infusion followed by Carboplatin via infusion every 21 days. Participants will complete up to 6 cycles of therapy as long as they are responding to therapy and not experiencing unacceptable side effects. Total study participation will last about 18 weeks.
Disease Status and/or Stage
Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Sponsor
Montefiore Medical Center
Key Eligibility
- Women age 18 and older
- Diagnosed with ovarian, primary peritoneal or fallopian tube cancer
- Must have received at least 1 prior platinum and taxane based chemotherapy regimen; may have failed no more than 2 prior chemotherapy regimens
- Must have "platinum sensitive" disease, meaning those with relapsed disease who had an initial complete remission, and then relapsed more than 6 months after completing initial platinum based chemotherapy
- Detailed eligibility reviewed when you contact the study team
Principal Investigator
Contact
- Dr. Gupta
- (212) 746-3307
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]
